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Introduction: Lung Clearance Index, measured using the multiple breath washout 
(MBW) technique, may be a useful test in infants with Cystic Fibrosis (CF). However, the 
requirement for specialised equipment and a number of important technical and 
methodological considerations relevant to testing in infants have complicated matters, and to 
date prevented its widespread translatability in this age group. 
 
Areas covered: We review the current status of infant MBW testing in CF, focusing 
on Lung Clearance Index. This includes a review of recent developments in the field relevant 
to testing methodology in the infant population, use in evaluating lung disease in CF in 
infancy, and the associated challenges which remain.   
 
Expert commentary: The challenges of infant MBW are not limited to those 
associated with testing equipment, but also gaps in our understanding regarding the 
interpretation of MBW indices in infants. This includes their relationship to underlying 
physiology and pathology, and tracking over time. Recent advances in understanding and 
improving the infant MBW test set up (including both hardware and software) relevant to 
infants will greatly progress the field. 
 
Keywords 
Cystic fibrosis, Infant lung function, Lung Clearance Index, Multiple Breath Washout, 
Clinical trials.   
1. Introduction 
Cystic fibrosis (CF) is a life shortening multi-system disease responsible for considerable 
morbidity, particularly affecting the respiratory system [1]. Repeated respiratory tract 
infections and thick respiratory secretions lead to irreversible lung damage and progressive 
decline in lung function, with disease progression already apparent in infancy and early 
childhood [2]. CF is included in national newborn screening programmes in many countries, 
with diagnosis made in the first few weeks of life. .  
 
There is a timely need to establish the role of multiple breath washout (MBW) in assessing 
CF lung disease in the first years of life. This test has potential both in the clinical monitoring 
of individuals, and as an outcome measure in clinical trials. We have entered an era where 
drugs which target the underlying molecular defect in the cystic fibrosis transmembrane 
conductance regulator (CFTR) have the potential to modify the disease course [3]. Whilst 
great success with drugs modulating CFTR function have been achieved in a small minority 
of the CF population [4, 5], results for those with the commonest disease causing mutations 
have been less impressive [6] and this remains a highly active research area where optimal 
outcome measures for clinical trials are of key importance.  Many outstanding questions 
remain, including whether such treatments should start in early life. It is therefore important 
that we have robust and clinically meaningful outcome measures in place relevant to this 
population.  
 
Interest in MBW as a lung function test in CF led to a workshop being convened by the North 
American Cystic Fibrosis Foundation in 2014 [7], to assess its role in multi-centre clinical 
trials across the paediatric age range, and in routine clinical care. Lung Clearance Index 
(LCI), measured using the MBW technique, has been suggested as a potential suitable test in 
infants with CF. However, there are a number of important methodological considerations 
relevant to testing in infants have complicated matters and to date prevented the widespread 
translatability of this test in this age group. Whilst acknowledging the evidence base for pre-
school age group, the workshop report listed that “gaps in knowledge about the choice of 
device, gas, and standardization across systems are key issues precluding its use as a clinical 
trial end point in infants”, and that “based on the current evidence, there are insufficient data 
to support the use of LCI or MBW parameters in the routine clinical management of patients 
with CF.” [7].  
 
This article reviews the current status of infant MBW testing in cystic fibrosis, focusing on 
LCI. It includes a review of recent developments in the field relevant to testing methodology 
in the infant population, use in evaluating lung disease in CF in infancy, and the associated 
challenges.  Many of the methodological issues associated with testing are not specific to 
infants with CF, but have the potential to significantly impact on results.   
2. Multiple breath washout  
The MBW technique was first described over 60 years ago [8], as a means of assessing 
homogeneity of ventilation and measurement of functional residual capacity (FRC). Its 
potential role in CF has been the focus of significant research interest, particularly over the 
past decade. The general principles of MBW testing are essentially summarised by its title – 
the ‘washout’ (i.e. the elimination) of a gas during tidal breathing is measured to determine 
clearance from the lungs and provide information on ‘ventilation homogeneity’ (efficiency of 
gas mixing). Higher LCI values reflect increased ventilation inhomogeneity (i.e. inefficient 
gas mixing). There are two main approaches – one involves ‘washing out’ resident nitrogen 
(N2) from the lungs with 100% oxygen, and the other uses an inert foreign tracer gas which is 
first ‘washed in’ and then ‘washed out’ of the lungs. For the latter, gases including sulphur 
hexafluoride (SF6), helium and argon have been used.  
In N2 washouts, resident nitrogen within the lung is washed out by breathing in 100% 
oxygen. In tests using a tracer gas such as SF6, the subject inspires a gas mixture containing a 
fixed percentage of this tracer until there is equilibrium between inspired and expired gas 
concentrations. This completes the washin stage of the test, at which point the test gas is 
disconnected and washout commences with the subject switched to breathing air. 
Measurement of expired gas allows detection of the point at which the end tidal concentration 
of the tracer gas (or N2 in the case of nitrogen washouts) falls below 1/40th of its initial 
concentration. Along with the simultaneous measurement of flow, these permit calculation of 
FRC by dividing the volume of exhaled tracer gas by its concentration in the lungs just before 
the start of the washout. Importantly, dead space created by equipment (e.g. facemask) is 
taken account of during calculations.  
It is increasingly recognised that the results derived from a MBW test using a tracer gas such 
as SF6, in comparison to those using N2 and 100% oxygen, are not interchangeable. Reasons 
for this include the potential for hypoventilation with inspiration of 100% oxygen, the 
contribution of endogenous tissue nitrogen when an N2 methodology is used, and that cut-off 
points for terminating washouts using tracer gases have been based on the original research 
involving N2 washouts and these may not be interchangeable.   
In observational research studies and clinical trials involving children and adults with CF, the 
main outputs from MBW tests have focused on Lung Clearance Index (LCI). Other indices 
such as moment ratios and phase III slope analysis remain largely in the research arena. The 
test is performed at rest, during tidal breathing and does not involve any forced expiratory 
manoeuvre hence its attractiveness for testing involving infants and young children. The LCI 
represents the number of lung volume turnovers to reduce the expired test gas concentration 
to 1/40th of the initial gas concentration (LCI = cumulative expired volume / functional 
residual capacity). It is important to appreciate that the LCI is therefore only able to assess 
ventilation homogeneity across regions of lung that are in communication during tidal 
breathing. The presence of e.g. mucus totally occluding an airway (as may occur in CF) 
would prevent assessment of ventilation inhomogeneity distal to that point, even if the distal 
airways were significantly diseased.  
3. MBW tests in infants 
MBW testing in infants involves a face mask being attached to a flowmeter and gas analyser, 
with putty used to ensure a good seal around the mask and prevent leak. Although MBW tests 
in older subjects with significant CF lung disease may be prolonged, tests in infants are 
generally shorter as younger children have a higher respiratory rate and milder lung disease. 
An SF6 washout in an infant can be completed within five minutes [9], with the entire test 
(i.e. 3 washout runs) completed within 20 minutes.  
 
There are important differences between equipment set up for MBW testing between infants, 
pre-school children and older subjects. These include the position of the subject (infant MBW 
tests are carried out with the subject supine in quiet sleep, whereas in pre-school children 
through to adulthood are carried out whilst sitting and awake). The supine position has the 
potential to influence the FRC, lung mechanics, and distribution of ventilation [9], however 
with the exception of a small study involving 12 infants and children ≤3years which found no 
difference in FRC between MBW tests performed supine and semi-erect in an infant safety 
seat [10], the authors are not aware of any other literature regarding the influence of body 
position in this age group. 
At our centre, infant lung function tests including MBW are carried out with oral sedation 
using chloral hydrate. Although this permits controlled testing conditions it may contribute to 
atelectasis, and tests cannot be repeated within short time intervals. MBW can also be carried 
out in unsedated infants during quiet sleep, particularly during the first 4 months of life but 
variability between tests may be greater [11].  
 
A further challenge for infant MBW tests is the influence of lung volumes on LCI. 
Schmalisch et al recently demonstrated that LCI was reduced in infants followed up after 
admission to neonatal intensive care with wheeze, and reported that this reduction was due to 
differences in lung volumes rather than reduced ventilation inhomogeneity [12]. The authors 
suggested that the association between LCI and lung volumes in infants could potentially lead 
to difficulties in interpreting homogeneity of ventilation.  
 
4. MBW testing equipment and applicability to infant testing 
The original studies involving MBW tests in infants with CF were conducted using a 
respiratory mass spectrometer (AMIS 2000, Innovision A/S, DK) and SF6 as the tracer gas 
[13], and has been considered the gold standard for testing. The development of commercial 
devices for the measurement of LCI in older children and adults has largely focused on 
nitrogen washouts (e.g. Exhalyzer D (Ecomedics AG, Switzerland) and EasyOne Pro (ndd 
Medizintechnik AG, Switzerland), however the Exhalyzer D has an option to use a tracer gas 
(4% SF6) for testing in infants, [14-18]. There are some concerns regarding the optimal 
configuration for the latter, and further modifications to the system are ongoing. Custom 
adaptations to the open circuit MBW method using the Innocor photoacoustic analyser 
(Innovision A/S, DK) with 0.2% SF6, discussed later in this review, have also been proposed 
to make it more suitable for infant testing. To the author’s knowledge, neither the 
commercially approved EasyOne Pro nor the closed circuit Innocor device for MBW testing 
have been tested in infants.  A further challenge for the infant field is that the AMIS 
respiratory mass spectrometer is no longer commercially available and thus limited to those 
centres with an existing machine.   
The preference for SF6 over nitrogen washouts in infants has centred on the concerns that 
breathing in 100% oxygen will alter the respiratory drive and result in hypoventilation [19, 
20], in turn affecting the variability of tidal volumes [21]. The influence of oxygen on 
breathing patterns in infants has been investigated by Singer et al [22]. They looked at the 
effect of inspiring 100% oxygen, and any potential benefit of giving a period of 40% oxygen 
to induce tolerance to the higher (100%) concentration in an effort to avert any impact on 
breathing patterns, in healthy controls (n=24) and infants with CF (n=15; 8 sedated) using an 
ultrasonic flowmeter setup. Hypoventilation occurred in both protocols, however within the 
two stage approach (40% increased to 100% oxygen), tolerance to hyperoxia occurred. The 
authors suggest this incremental protocol as a means of eliminating the effect on breathing 
patterns when nitrogen washouts using 100% O2 are used [22], and provide an interesting 
alternative to SF6 based tests in infancy. 
Use of SF6 is not problem free -  the gas has harmful environmental impact associated with 
climate change[23]. Mass spectrometers and ultrasonic flowmeter set ups using SF6 typically 
use around 4% tracer gas, whereas the open circuit modified Innocor uses a much lower 
concentration (0.2%)[24].  
It is not possible to simply combine or consider equivalent MBW tests using different 
equipment set ups, as the results are not comparable. Discrepancies exist due to factors such 
as equipment dead space, type of washout (N2 or tracer gas), and settings within software for 
analysis (either custom made or commercial). Detailed standard operating procedures are 
needed to minimise differences between centres using the same equipment.  The requirement 
for specialised equipment, appropriately trained staff and (where performed) the ability to 
manage sedated infants has meant that infant MBW testing remains largely in the research 
arena.  
 
5. Masks and dead space 
The volume of dead space contributed to by e.g. the face mask used for testing has particular 
importance in infancy given the relative large ratio of equipment dead space to an 
individual’s lung volumes. Meticulous attention is given by those performing infant MBW 
tests to minimise this, as different dead space volumes (e.g. between types of mask) can have 
a significant impact on LCI results [25, 26]. Benseler et al [27] have recently reported the 
impact of dead space volume on LCI results using both a nitrogen washout set up (Exhalyzer 
D), and SF6 set up (using the Amis 2000 respiratory mass spectrometer, Innovision A/S) with 
in vivo measurements performed in adults (and then pre-schoolers with CF and controls), and 
applied their results to the impact on LCI in pre-schoolers. They found that increases in 
equipment dead space resulted in higher LCI when using the nitrogen MBW set up, and that 
differences in LCI values when measured by the two systems were reduced when the dead 
space was equivalent in each [27], although the contribution of endogenous tissue nitrogen 
and potential impact on breathing patterns resulting from 100% oxygen may also contribute 
to differences between setups.   
6. Influence of software algorithms on infant MBW in CF 
The analysis of MBW tests is dependent on software specific to the set up, often conducted 
off line at conclusion of testing. With the increasing availability of commercially accessible 
equipment and software for MBW testing, the move has been towards automating output and 
minimising the input required from the operator for washout settings. Using an ultrasonic 
flowmeter MBW set up (Exhalyzer D) with 4% SF6 as the tracer gas and Wbreath software 
(ndd, Medizintechnik AG, Zurich, Switzerland) Anagnostopoulou et al reported that the 
software algorithm used influenced the LCI result for infants with CF [28]. The method relies 
on an indirect calculation of the inert gas concentration by analysing changes in mainstream 
molar mass. Anagnostopoulou found that by applying automatic rather than manual settings 
for the software algorithms resulted in a significantly lower LCI, largely due to discrepancies 
between the two algorithms in detecting the end of the washout [28].  
7. MBW set ups and accuracy in infancy 
One reason for the attractiveness of mass spectrometry for infant MBW has reflected their 
rapid gas analyser times. A very fast response time is important in infants due to their 
increased respiratory rate in comparison to older subjects. In this respect, a limitation of the 
open circuit Innocor MBW set ups has been in its gas analyser response time exceeding 100 
milliseconds. However in-house adaptations to the Innocor device have been performed by 
Horsley, which reduced this from 154 to 88 milliseconds [29], and tested in a lung model 
system for accuracy of FRC volume calculation. At lung volumes relevant to infant testing, 
these modifications were successful in FRC measurement with a high degree of accuracy.   
In view of the challenges of reducing dead space volumes, and difficulties with accessing 
mass spectrometry Shawcross et al have recently described a set up for MBW tests which in 
in vitro testing using a simulated lung model, suggest may have a role in infant testing [30]. 
Their set up uses the Innocor device with SF6 as the tracer gas, but instead of integrating a 
flowmeter within the testing circuit, the expired gas is analysed at termination of the washout, 
following which the cumulative expired volume, FRC and therefore LCI are calculated. The 
absence of inclusion of a flowmeter within the testing circuit leads to a reduction in 
deadspace, and calculation of LCI does not rely on the integration of flow and gas signals. 
Shawcross et al have determined that this set up resulted in an accurate FRC measurements 
(within 5% in >90% tests).  
Accuracy of the ultrasonic flowmeter Exhalzyer D (EcoMedics) has also been investigated 
using this lung model. Singer et al investigated the Exhalyzer D nitrogen washout and 
reported that 43% tests met this same degree of accuracy in their “small lung” model (100-
400ml FRC), with more favourable results in tests with higher FRC [31]. More recently, 
using the same lung model as Singer, Schmidt et al investigated two Exhalyzer D MBW set 
ups, using SF6 and helium as tracer gases [32]. They used SF6 (4%) for the infant set up and 
helium (20%) for a ‘young child’ set up. In their infant lung model, the MBW SF6 set up gave 
a relative difference between model and measured FRC of mean(SD)  0.7(4.7)% at volumes 
between 80-300ml.  
8. Improving the feasibility of MBW in infants  
The ERS/ATS consensus recommendations for MBW testing recommend that mean FRC is 
reported from three technically acceptable measurements [33]. Pre-school guidelines for 
MBW had recommended that two technically acceptable tests with FRC within 10% of each 
other were sufficient for calculating mean FRC and LCI [34]. Robinson et al investigated the 
feasibility of using this ‘abbreviated’ MBW testing protocol across the paediatric age range, 
from infancy, in healthy controls and CF [35]. They concluded that the recommendation for 
two rather than three technically acceptable tests (irrespective of differences in FRC between 
tests) was appropriate and that this did not unduly affect LCI.  
Although not from infants, Yammine et al used nitrogen MBW (using the Exhalyzer D, 
EcoMedics AG, Switzerland) in school age children to look at the influence on test sensitivity 
and specificity and duration, using a number of strategies aimed at shortening the test (and 
thereby improving its acceptability). They found that performing either three MBW runs to 
1/20th (rather than the ‘standard’ 1/40th) of the nitrogen starting concentration, or two runs 
until 1/40th both significantly reduced the time taken for MBW testing in children without 
adversely affecting diagnostic performance [36].  
Respiratory sighs in infants have been suggested as exclusion criteria for analysis in MBW 
testing recommendations [33]. MBW was measured in infants between 4-12 weeks of age 
during natural sleep using an ultrasonic flowmeter and SF6 as the tracer gas (Exhalyzer D, 
Ecomedics) by Vukcevic et al. They found that sighs occurred in 119/767 (15%) of infant 
MBW tests and that when occurring in the washout phase of testing impacted on results, with 
sighs resulting in elevated LCI (mean(95% CI)  LCI increased by 0.36(0.11 to 0.62) units 
with variance increasing by a factor of two) [37]. However,  there was negligible impact on 
LCI when sighs occurred during the washin phase, leading the authors to suggest that these 
tests need not be excluded thus increasing the proportion of technically satisfactory tests.  
9. MBW indices other than LCI 
As an outcome from the MBW test, LCI has received by far the most attention but many 
indices can be calculated and some are being subjected to renewed interest [33]. These 
indices are often accompanied by their own challenges in terms of relevance and 
interpretation for infant MBW. For example, moment ratios (which take into account area 
under the washout curve) are reported far less commonly than LCI, and methodology 
appropriate to infant tests has not been standardised. More generally, it may be that 
historically used cut points to indicate termination of the MBW test need some adjustment to 
optimise the discriminatory ability of LCI to detect ventilation inhomogeneity. Furthermore, 
the assumption that the same cut of (1/40th) is equitable between washouts using different 
tracer gases has recently been challenged. Yammine et al compared the impact of using a 
2.5% (1/40th) cut off for terminating a nitrogen and foreign (e.g. SF6)  tracer gas washout (by 
taking account of endogenous nitrogen to make the nitrogen washout comparable to one 
carried out using a foreign tracer gas)[38]. They found that the contribution of tissue nitrogen 
had a sizable, clinically relevant impact on LCI and FRC and suggested that a cut off of 1.5% 
for SF6 washouts may be more comparable to N2 washouts using 2.5% cut off.  
Egger et al have investigated the use of the 1/40th cut point (i.e. 2.5% of the starting tracer gas 
concentration) in SF6 washouts for both LCI and moment ratios in infancy. They found 
optimal discriminative power for moment ratios and LCI to detect differences between 
healthy controls and infants with cystic fibrosis at 1.5% tracer gas concentration [39].  
10. The role of reference data for interpreting infant LCI 
In older children (>6yrs) and adults, LCI is stable in health and therefore can be reported as 
an absolute value. In the early years, LCI has been noted to be elevated and therefore 
standardization with z scores permits comparison between longitudinal measurements. 
Collated data from three centres was used to investigate the age and height dependence of 
lung clearance index in health. Lum et al collected data on nearly 500 children across the 
paediatric age range, from 2 weeks to 19 years of age, on >650 occasions [40]. Mass 
spectrometry with 4% SF6 was used for the MBW tests. They found that there was an age and 
height dependence of LCI in infancy, with LCI dependent on body size. Particularly in the 
first five years of life, LCI was found to decrease non-linearly with increasing height. Height, 
age and sex were all independent predictors of FRC. Reference equations for the calculation 
of z scores using the lambda-mu-sigma (LMS) method were created, which permit 
interpretation of results. However it is important to note that these equations will only be 
applicable to LCI as measured with the same test set-up, creating an added complexity to a 
field where comparisons between centres and devices is challenging. Conversion of LCI to z 
scores using data from healthy controls obtained using the same equipment is important for 
interpretation particularly when tracking disease over time. This in itself creates a challenge 
for the field. It is important that reference equations are relevant to the equipment being used 
and the population of interest, and that if appropriate reference data is not available, 
measurements are made on contemporaneous healthy controls in order to benchmark the 
results appropriately.  
11. Relationship to other infant lung function tests 
The order in which infant lung function tests are performed has the potential to influences the 
results obtained, as such careful consideration must be given when planning testing protocols 
which involve multiple lung function tests in addition to MBW. Subbarao and colleagues 
have looked at the influence of raised volume rapid thoracic compression (RVRTC) 
manoeuvres on MBW measurements in infants [41]. Their testing protocol sequence involved 
MBW, RVRTC, and then repeat MBW, with infants sedated using oral chloral hydrate and 
using the AMIS mass spectrometer (Innovision, DK) with an SF6/Helium gas mixture. They 
found that performing the forced respiratory manoeuvres in RVRTC testing prior to MBW 
resulted in reductions in FRC and (to a greater extent) cumulative expired volume, with such 
changes particularly noted in infants with respiratory disease (CF or wheeze). 
12. MBW in infants with CF 
To date, it has not been clearly established how infant LCI measurements relate to those 
performed in later childhood. It is also important that we determine the implications of LCI 
values in infancy, and how they relate to structural abnormalities, clinical parameters, and 
infection and inflammation on a cross sectional and longitudinal basis. It should also be 
remembered that SF6 and N2 washouts are not interchangeable, yet the bulk of evidence 
which has been built up over the past two decades on the utility of MBW and LCI in CF lung 
disease was carried out using the SF6 method and respiratory mass spectrometry. Therefore 
we cannot be certain that results from N2 washouts would correlate with other parameters or 
represent the extent of disease in the same way. 12.1 Change in LCI over time 
In infants with CF diagnosed by newborn screening (NBS), the proportion with an abnormal 
LCI at around 3 months of age and 1 year is relatively low. The London Cystic Fibrosis 
Collaboration (LCFC, https://www.ucl.ac.uk/london-cystic-fibrosis) is following up a cohort 
of NBS infants with CF, and contemporaneous healthy controls. CF infants and healthy 
controls had lung function tests performed under sedation at around 3 months of age and one 
year, including MBW with respiratory mass spectrometry (AMIS 2000) and SF6 as the tracer 
gas. The proportion with an abnormal LCI (>1.96z) at these time points was 17% (12/71) and 
18% (13/71) respectively [42].  This cohort continues to be followed up, but the proportion of 
children with an elevated LCI in a clinically diagnosed cohort (recruited before the start of 
national NBS in the UK) increased during childhood [43, 44]. The Australian Respiratory 
Early Surveillance Team for CF (AREST-CF) have similarly reported that the vast majority 
of infants with CF diagnosed by NBS have normal LCI results [45], although direct 
comparisons with the LCFC cohort are not possible due to the use of different MBW set ups 
(Exhalyzer D vs AMIS 2000 mass spectrometry) and absence of contemporaneous healthy 
controls in the AREST-CF study.  
In pre-school children with CF diagnosed clinically, LCI has been shown to track to school 
age [43] but an evidence base to support tracking through infant measurements is currently 
lacking. The LCFC has shown that LCI measured by mass spectrometry tracked from 
3months to 1year of age in NBS CF infants [42], but interestingly there was no tracking 
between tests performed (in a non-interventional setting) at around 1 and 2 years of age [46] . 
Given this lack of tracking between 1-2 years of age, the clinical interpretation of an apparent 
‘improvement’ in LCI, from those with an ‘abnormal’ result at early infant timepoints (e.g. 
3mths) which ‘normalises’ by 1yr or 2yrs remains to be determined. The LCFC has recently 
completed testing the NBS CF cohort at pre-school age, and results are eagerly awaited.  
Although small in terms of patient numbers, a single centre retrospective study from 
Switzerland using the Exhalyzer D MBW set up reported paired infant and school age 
measurements from 11 children with CF (MBW measured with SF6 in infants and N2 in 
school age children), providing some evidence for the ability of infant LCI to track through to 
school age [47].  
Longitudinal cohort studies such as those performed by the LCFC and AREST-CF groups 
will help us to understand the variability of LCI in CF, and how it changes in response to 
routine or novel therapies in the first years of life. 
12.2 Relation to chest CT 
Lung clearance index has been shown to correlate more closely than spirometry in pre-school 
and school age children with CF to structural lung disease on chest computed tomography 
(CT)[48-50]. In sixty school age children with CF diagnosed clinically (mean age 7.8yrs), 
total CT score correlated strongly with LCI, however in individual patients LCI and chest CT 
were considered complimentary to each other: 5/9 children with normal LCI had 
abnormalities on HRCT, whereas five children with normal HRCT had raised LCI [50]. In 
infants, the relationship between LCI and structural evidence of CF lung disease on chest CT 
is less clear. The AREST-CF group found no association between LCI (measured using an 
ultrasonic flowmeter (EcoMedics, Switzerland) and 5% SF6) and neither the presence of 
bronchiectasis nor air trapping, but that moment ratios may reflect evidence of structural lung 
disease in infants with CF [51]. Ramsey et al have recently investigated relationships between 
structural outcomes (chest CT) and LCI across the paediatric age range [45]. They looked at 
the association between structural lung disease and LCI measured using the Exhalyzer D 
using 4% SF6, and in infants found poor correlation between LCI and structural lung disease 
(k =20.03 [95% confidence interval, 20.05 to 0.16]), with LCI having low negative predictive 
value for bronchiectasis and air trapping. In contrast, in older children LCI (measured with 
the Exhalyzer D N2 set up) values were more closely associated with evidence of lung disease 
on chest CT: in pre-school and school age children LCI correlated with total structural 
disease extent and additionally at school age with extent of bronchiectasis and air trapping. 
An added complexity when investigating relationships between abnormal functional and 
structural outcomes is introduced by their prevalence – particularly if abnormalities are rare 
and mild, as we have observed with chest CT in NBS CF infants in the LCFC cohort [52]. 
The difficulties with mapping LCI to structural abnormalities do not preclude its potential 
usefulness in this age group, but further evidence is needed regarding the significance of an 
elevated LCI in the context of a normal chest CT. It may be that an elevated LCI in the 
absence of structural abnormalities on chest CT is instead reflects inflammation and 
infection, as described in section 12.3 below.  
12.3 Relation to infection 
The AREST-CF group recently published the association between infant LCI and pulmonary 
infection. They performed MBW testing and bronchoalveolar lavage(BAL) at three time 
points in the first 2 years of life in 108 infants with CF. They found that significant 
pulmonary infection (particularly with Haemophilus influenzae) was associated with 
concurrent elevation in LCI, and that deficits in ventilation homogeneity persisted over time 
[53]. Using the Exhalyzer D ultrasonic flowmeter with SF6 as the tracer gas, Belessis et al 
found that LCI in CF infants (mean age 1.55 years) was elevated in comparison to healthy 
controls, and that within the CF subjects the presence of Pseudomonas aeruginosa and 
evidence of airway inflammation on bronchoalveolar lavage was associated with elevated 
LCI [16].  
13. Infant LCI as an outcome measure in CF clinical trials 
LCI has established a role in the assessment of pre-school children with CF and in older 
subjects with normal spirometry, and has been used as an outcome measure in clinical trials. 
It has been used successfully as a primary outcome measure in a phase II clinical trial of the 
CFTR modulator ivacaftor involving CF patients aged 6yrs and over with normal spirometry 
(forced expiratory volume in 1 second >90% predicted) [54], where a significant treatment 
effect was detected. In school age children with CF LCI has successfully demonstrated a 
significant treatment effect for dornase alpha and hypertonic saline [55, 56]. 
There has been limited use of MBW in clinical trials involving infants with CF to date. A 
clinical trial of inhaled hypertonic saline in infants and children less than 6yrs old with CF 
(the ISIS study)[57], has explored LCI as an endpoint, where it was included in the trial 
protocol as an exploratory outcome. This study was a multicentre, randomized, controlled 
trial of 7% vs 0.9% nebulised saline twice daily for 48 weeks. LCI was measured at a single 
site, in a sub-group of the study population. Acceptable LCI measurements were obtained in 
25/27 participants at baseline and at the end of the trial, using mass spectrometry (AMIS 
2000; Innovision) and SF6 as the tracer gas [57]. The median age of participants in this 
substudy was 2.6 years (range 0.34 to 4.95yrs), crossing into the pre-school years. Infant lung 
function tests were performed under sedation in those <16 months of age in a supine position, 
whereas those >16 months were performed awake and seated.  LCI results were converted to 
z scores for interpretation [40]. 4/12 children in the hypertonic saline group were infants, in 
comparison to 6/13 in the isotonic saline group. Due to the low n numbers, interpretation of 
LCI results is limited. However although not powered, the authors noted that infants 
randomised to treatment with hypertonic saline did not  show change in LCI, whereas an 
increased LCI (suggestive of deterioration) over the 48 week study period was observed in 
those receiving isotonic saline [57]. These results contrasted to those in children from the pre-
school age group, where changes suggestive of improvement were observed in those 
receiving the hypertonic solution. Importantly, the authors of the ISIS study suggested that 
MBW testing was feasible in a single centre interventional study in infants and preschool 
children with CF. A challenge for all potential efficacy outcome measures in early life is how 
they compare to healthy controls, i.e. whether there are any detectable deficits by timepoints 
potentially measured by infant lung function tests such as MBW. As described above, the 
LCFC and AREST-CF cohort studies have both shown that the vast majority of infants with 
CF diagnosed by NBS have normal LCI values. In the ISIS study, all infants had a normal 
LCI at their baseline measurement.  
14. Challenges, conclusions and the future 
This article has reviewed the use of MBW testing in infants with CF, along with a number of 
recent developments relevant to the field relating to methodology both within and between 
different MBW set ups. However it is not only technical aspects that need to be resolved, but 
also that we better understand the interpretation of MBW indices – in terms of relationship to 
underlying physiology and pathology – in our youngest patients with CF.  
15. Expert commentary 
The challenges of infant MBW are not limited to those associated with testing equipment, but 
also gaps in our understanding regarding the interpretation of MBW indices in infants. This 
includes their relationship to underlying physiology and pathology, and tracking over time. 
Recent advances in understanding and improving the infant MBW test set up (including both 
hardware and software) relevant to infants will greatly progress the field. New therapies 
targeting the basic defect in CF make it even more important that the field embraces these 
outstanding questions to determine whether infant MBW should or could play a role in 
evaluating their efficacy, or in its role in longitudinal follow up in routine care. There remains 
a great deal of work to standardise measurements and analysis and improve the translatability 
of infant MBW testing. Given the rapidly evolving field of new treatments for CF which have 
the potential to modify disease, this is an opportunity that cannot afford to be missed. 
16. Five year view 
Over the past decade, MBW testing has established itself as a key player in evaluating CF 
lung disease in older children and adults with mild lung disease. However, it is likely that 
infant MBW testing will remain in the research setting for the foreseeable future.  By five 
years’ time we should be better placed to understand the clinical significance of infant MBW 
tests, and to determine which (if any) ‘key’ testing points in infancy track to measures made 
in the pre-school years and beyond.   
17. Key issues 
 
• Many indices can be calculated from the Multiple Breath Washout test, but the focus 
has been on Lung Clearance Index (LCI) 
• In children of pre-school age and above, there is evidence that LCI correlates with 
structural lung disease on chest imaging however this relationship is less clear in 
infants.  
• The preference for inert tracer gases such as SF6 in infant MBW stems from evidence 
that the high concentrations of oxygen required for nitrogen washouts affect the 
breathing pattern in infants and thus influence LCI.  
• Infant MBW testing is largely limited to the research setting. There is a single 
commercially available option for performing tests, and the historically considered 
‘gold standard’ method using respiratory mass spectrometry is limited to existing 
centres as no longer commercially available.  
• LCI results are not consistent across different test set ups, and small changes e.g. to 
mask size or software settings can impact greatly on results.  
• There is a need for respiratory outcome measures for clinical trials of novel treatments 
in the first years of life, but the evidence base to support infant MBW in this role is 
currently lacking.  
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